J Korean Endocr Soc.  2008 Feb;23(1):9-14. 10.3803/jkes.2008.23.1.9.

Endocrine Disorders and Dyslipidemia

• Hong YS

• KMID: 2063544
• DOI: http://doi.org/10.3803/jkes.2008.23.1.9

Abstract

No abstract available.

MeSH Terms

Dyslipidemias

Figure

• 

  Fig. 1 Dyslipidemia in type 2 diabetes mellitus and metabolic syndrome.

• 

  Fig. 2 The effect of thyroid hormone on lipid metabolism. CETP, cholesteryl ester transfer protein; LPL, lipoprotein lipase; NEFA, non-esterified fatty acid; CE, cholesteryl ester; TG, triglyceride.

Reference

1. Stone NJ. Secondary causes of hyperlipidemia. Med Clin North Am. 1994. 78:117–141.

2. Chait A, Brunzell JD. Acquired hyperlipidemia (secondary dyslipoproteinemias). Endocrinol Metab Clin North Am. 1990. 19:259–278.

3. Durrington PN. Secondary hyperlipidaemia. Br Med Bull. 1990. 46:1005–1024.

4. Koppers LE, Palumbo PJ. Lipid disturbances in endocrine disorders. Med Clin North Am. 1972. 56:1013–1020.

5. Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care. 2004. 27:1496–1504.

6. Avramoglu RK, Basciano H, Adeli K. Lipid and lipoprotein dysregulation in insulin resistant states. Clin Chim Acta. 2006. 368:1–19.

7. Kolovou GD, Anagnostopoulou KK, Cokkinos DV. Pathophysiology of dyslipidaemia in the metabolic syndrome. Postgrad Med J. 2005. 81:358–366.

8. Haffner SM. Lipoprotein disorders associated with type 2 diabetes mellitus and insulin resistance. Am J Cardiol. 2002. 90:suppl. 55i–61i.

9. Deeb SS, Zambon A, Carr MC, Ayyobi AF, Brunzell JD. Hepatic lipase and dyslipidemia: Interactions among genetic variants, obesity, gender, and diet. J Lipid Res. 2003. 44:1279–1286.

10. Hirano T. Lipoprotein abnormalities in diabetic nephropathy. Kidney Int Suppl. 1999. 71:S22–S24.

11. Shin DJ, Osborne TF. Thyroid hormone regulation and cholesterol metabolism are connected through sterol regulatory element-binding protein-2(SREBP-2). J Biol Chem. 2003. 278:34114–34118.

12. Duntas LH. Thyroid disease and lipids. Thyroid. 2002. 12:287–293.

13. Walsh JP, Bremner AP, Bulsara MK, O'Leary P, Leedman PJ, Feddema P, Michelangeli V. Thyroid dysfunction and serum lipids: a community-based study. Clin Endocrinol Oxf. 2005. 63:670–675.

14. Cappola AR, Ladenson PW. Hypothyroidism and atherosclerosis. J Clin Endocrinol Metab. 2003. 88:2438–2444.

15. Pucci E, Chiovato L, Pinchera A. Thyroid and lipid metabolism. Int J Obes Relat Metab Disord. 2000. 24:suppl 2. S109–S112.

16. Brenta G, Berg G, Arias P, Zago V, Schnitman M, Muzzio ML, Sinay I, Schreier L. Lipoprotein alterations, hepatic lipase activity and insulin sensitivity in subclinical hypothyroidism: response to L-T4 treatment. Thyroid. 2007. 17:453–460.

17. Grundy SM. Thyroid mimetic as an option for lowering low-density lipoprotein. Proc Natl Acad Sci U S A. 2008. 105:409–410.

18. De Boer H, Block GJ, Voerman HJ, Phillips M, Schouten JA. Serum lipid levels in growth hormonedeficient men. Metabolism. 1994. 43:199–203.

19. Kearney T, De Gallegos CN, Chrisoulidou A, Gray R, Bannister P, Venkatesan S, Johnston DG. Hypopituitarism is associated with triglyceride enrichment of very low-density lipoprotein. J Clin Endocrinol Metab. 2001. 86:3900–3906.

20. Carroll PV, Christ ER, Bentsson BA, Carlsson I, Christiansen JS, Clemmons D, Hintz R, Ho KY, Laron Z, Sizonenko P, Sonksen PH, Tanaka T, Thorner MO. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J Clin Endocrinol Metab. 1998. 83:382–395.

21. Beentjes JAM, Van Tol A, Sluiter W, Dullaart RPF. Effect of growth hormone replacement therapy on plasma lecithin:cholesterol acyltransferase activity and lipid transfer protein activities in growth hormone deficient adults. J Lipid Res. 2000. 41:925–932.

22. Parkinson C, Drake WM, Wieringa G, Yates AP, Besser GM, Trainer PJ. Serum lipoprotein changes following IGF-1 normalization using a growth hormone receptor antagonist in acromegaly. Clin Endocrinol Oxf. 2002. 56:303–311.

23. Beentjes JAM, Van Tol A, Sluiter Wj, Dullaart RPF. Low plasma lecithin:cholesterol acyltransferase and lipid transfer protein activities in growth hormone deficient and acromegalic men: role in altered high density lipoproteins. Atherosclerosis. 2000. 153:491–498.

24. Rafnsson AT, Johannsson M, Olafsson I, Dallongeville J, Erfurth EM, Berg AL, Arnadottir M. Effects of different doses of adrenocorticotrophic hormone on the serum lipoprotein profile in healthy subjects. Basic Clin Pharmacol Toxicol. 2005. 97:86–90.

25. Skoog M, Xu N, Berggren-Söderlund M, Lovegrove JA, Nilsson-Ehle P. ACTH reduces the rise in ApoB-48 levels after fat intake. Atherosclerosis. 2007. 191:433–439.

26. Johnston DG, Alberti KGMM, Nattrass M, Barnes AJ, Bloom SR, Jpolin GF. Hormonal and metabolic rhythms in Cushing's syndrome. Metabolism. 1980. 29:1046–1052.

27. Ottosson M, Vikman-Adolfsson K, Enerbäck S, Olivercrona G, Björntorp P. The effects of cortisol on the regulation of lipoprotein lipase activity in human adipose tissue. J Clin Endocrinol Metab. 1994. 79:820–825.

28. Arnaldi G, Mancini T, Polenta B, Boscaro M. Cardiovascular risk in Cushing's syndrome. Pituitary. 2004. 7:253–256.

29. Friedman TC, Mastorakos G, Newman TD, Mullen NM, Horton EG, Costello R, Papadopoulos NM, Chrousos GP. Carbohydrate and lipid metabolism in endogenous hypercortisolism: Shared features with metabolic syndrome X and NIDDM. Endocrine J. 1996. 43:645–655.

30. Mancini T, Kola B, Mantero F, Boscaro M, Arnaldi G. High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol Oxf. 2004. 61:768–777.

31. Fraser R, Ingram MC, Anderson NH, Morrison C, Davies E, Connell JMC. Cortisol effects on body mass, blood pressure, and cholesterol in the general population. Hypertension. 1999. 33:1364–1368.

32. Bayrak A, Aldemir D, Bayrak T, Corakci A, Dursun P. The effect of hormone replacement therapy on the levels of serum lipids, apolipoprotein A1, apolipoprotein B and lipoprotein(a) in Turkish postmenopausal women. Arch Gynecol Obstet. 2006. 274:289–296.

33. Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein and apolipoprotein(a) concentrations: analysis of studies published from 1974-2000. Fertil Steril. 2001. 75:898–915.

34. Campos H, Walsh BW, Judge H, Sacks FM. Effect of estrogen on very low-density lipoprotein and low-density lipoprotein subclass metabolism in postmenopausal women. J Clin Endocrinol Metab. 1997. 82:3955–3963.

35. Van Pottelbergh I, Braeckman L, De Bacquer D, DeBacker G, Kaufman JM. Differential contribution of testosterone and estradiol in the determination of cholesterol and lipoprotein profile in healthy middle-aged men. Atherosclerosis. 2003. 166:95–102.

36. Haffner SM, Mykkänen L, Valdez RA, Katz MS. Relationship of sex hormones to lipids and lipoproteins in nondiabetic men. J Clin Endocrinol Metab. 1993. 77:1610–1615.

37. Schleich F, Legros JJ. Effects of androgen substitution on lipid profile in the adult and aging hypogonadal male. Eur J Endocrinol. 2004. 151:415–424.

38. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med. 2001. 111:607–613.

39. Valkenburg O, Steegers-Theunissen RP, Smedts HP, Dallinga-Thie GM, Fauser BC, Westerveld EH, Laven JS. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study. J Clin Endocrinol Metab. 2008. 93:470–476.

40. Diamanti-Kandarakis E, Papavassiliou AG, Kandarakis SA, Chrousos GP. Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metab. 2007. 18:280–285.

41. Herrera E, Amusquivar E, Lopez-Soldado I, Ortega H. Maternal lipid metabolism and placental lipid transfer. Horm Res. 2006. 65:Suppl 3. 59–64.